Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

A UNIQUE CDK4/6 INHIBITOR: CURRENT AND FUTURE THERAPEUTIC STRATEGIES OF ABEMACICLIB.

Chong QY, Kok ZH, Bui NL, Xiang X, Li-Ann Wong A, Peng Yong W, Sethi G, Lobie PE, Wang L, Goh BC.

Pharmacol Res. 2020 Feb 14:104686. doi: 10.1016/j.phrs.2020.104686. [Epub ahead of print] Review.

PMID:
32068118
2.

DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.

Sundar R, Ng A, Zouridis H, Padmanabhan N, Sheng T, Zhang S, Lee MH, Ooi WF, Qamra A, Inam I, Hewitt LC, So JB, Koh V, Nankivell MG, Langley RE, Allum WH, Cunningham D, Rozen SG, Yong WP, Grabsch HI, Tan P.

Eur J Cancer. 2019 Dec;123:48-57. doi: 10.1016/j.ejca.2019.09.016. Epub 2019 Oct 23.

PMID:
31655359
3.

FBXW5 Promotes Tumorigenesis and Metastasis in Gastric Cancer via Activation of the FAK-Src Signaling Pathway.

Yeo MS, Subhash VV, Suda K, Balcıoğlu HE, Zhou S, Thuya WL, Loh XY, Jammula S, Peethala PC, Tan SH, Xie C, Wong FY, Ladoux B, Ito Y, Yang H, Goh BC, Wang L, Yong WP.

Cancers (Basel). 2019 Jun 17;11(6). pii: E836. doi: 10.3390/cancers11060836.

4.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

5.

Study protocol: phase 1 dose escalating study of Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) with oxaliplatin in peritoneal metastasis.

Kim G, Tan HL, Chen E, Teo SC, Jang CJM, Ho J, Ang Y, Ngoi NYL, Chee CE, Lieske B, Shabbir A, Wang LZ, So JBY, Yong WP.

Pleura Peritoneum. 2018 Aug 29;3(3):20180118. doi: 10.1515/pp-2018-0118. eCollection 2018 Sep 1.

6.

Predictors of survival outcome following radical gastrectomy for gastric cancer.

Lui SA, Tan WB, Tai BC, Yong WP, Mu YS, Ti TK, Shabbir A, So J.

ANZ J Surg. 2019 Jan;89(1-2):84-89. doi: 10.1111/ans.15011. Epub 2019 Jan 28.

PMID:
30690932
7.

An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma.

El Dika I, Lim HY, Yong WP, Lin CC, Yoon JH, Modiano M, Freilich B, Choi HJ, Chao TY, Kelley RK, Brown J, Knox J, Ryoo BY, Yau T, Abou-Alfa GK.

Oncologist. 2019 Jun;24(6):747-e218. doi: 10.1634/theoncologist.2018-0838. Epub 2018 Dec 31.

8.

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs.

Wong AL, Xiang X, Ong PS, Mitchell EQY, Syn N, Wee I, Kumar AP, Yong WP, Sethi G, Goh BC, Ho PC, Wang L.

Pharmaceutics. 2018 Nov 8;10(4). pii: E221. doi: 10.3390/pharmaceutics10040221. Review.

9.

The Role of Liver-Directed Therapy in Metastatic Colorectal Cancer.

Tan HL, Lee M, Vellayappan BA, Neo WT, Yong WP.

Curr Colorectal Cancer Rep. 2018;14(5):129-137. doi: 10.1007/s11888-018-0409-6. Epub 2018 Sep 13. Review.

10.

An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models.

Osanai-Sasakawa A, Hosomi K, Sumitomo Y, Takizawa T, Tomura-Suruki S, Imaizumi M, Kasai N, Poh TW, Yamano K, Yong WP, Kono K, Nakamura S, Ishii T, Nakai R.

Am J Cancer Res. 2018 Aug 1;8(8):1499-1513. eCollection 2018.

11.

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor.

Subhash VV, Yeo MS, Wang L, Tan SH, Wong FY, Thuya WL, Tan WL, Peethala PC, Soe MY, Tan DSP, Padmanabhan N, Baloglu E, Shacham S, Tan P, Koeffler HP, Yong WP.

Sci Rep. 2018 Aug 16;8(1):12248. doi: 10.1038/s41598-018-30686-1.

12.

A Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Nimbolide in Mouse Serum: Application to a Preclinical Pharmacokinetics Study.

Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL, Yang S, Wong AL, Kumar AP, Yong WP, Sethi G, Ho PC, Goh BC.

Pharmaceutics. 2018 Aug 8;10(3). pii: E123. doi: 10.3390/pharmaceutics10030123.

13.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.

Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).

Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

14.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
15.

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.

Limviphuvadh V, Tan CS, Konishi F, Jenjaroenpun P, Xiang JS, Kremenska Y, Mu YS, Syn N, Lee SC, Soo RA, Eisenhaber F, Maurer-Stroh S, Yong WP.

BMC Cancer. 2018 May 11;18(1):555. doi: 10.1186/s12885-018-4471-x.

16.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

17.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.

Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP.

BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.

18.

Longitudinal monitoring reveals dynamic changes in circulating tumor cells (CTCs) and CTC-associated miRNAs in response to chemotherapy in metastatic colorectal cancer patients.

Tan K, Leong SM, Kee Z, Caramat PV, Teo J, Blanco MVM, Koay ESC, Cheong WK, Soh TI, Yong WP, Pang A.

Cancer Lett. 2018 Jun 1;423:1-8. doi: 10.1016/j.canlet.2018.02.039. Epub 2018 Mar 5.

PMID:
29518480
19.

Resisting resistance to cancer immunotherapy.

Lam WS, Wang LZ, Roudi R, Yong WP, Syn NL, Sundar R.

Thorac Cancer. 2018 May;9(5):507-508. doi: 10.1111/1759-7714.12614. Epub 2018 Mar 7. No abstract available.

20.

Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.

Wang L, Syn NL, Subhash VV, Any Y, Thuya WL, Cheow ESH, Kong L, Yu F, Peethala PC, Wong AL, Laljibhai HJ, Chinnathambi A, Ong PS, Ho PC, Sethi G, Yong WP, Goh BC.

Cancer Lett. 2018 Mar 28;417:152-160. doi: 10.1016/j.canlet.2017.12.030. Epub 2018 Jan 4.

PMID:
29306016

Supplemental Content

Loading ...
Support Center